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Abstract
The substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) contain the two
largest populations of dopamine (DA)-releasing neurons in the mammalian brain. These neurons
extend elaborate projections in striatum, a large subcortical structure implicated in motor planning
and reward-based learning. Phasic activation of dopaminergic neurons in response to salient or
reward-predicting stimuli is thought to modulate striatal output via the release of DA to promote
and reinforce motor action1–4. Here we show that activation of DA neurons in striatal slices
rapidly inhibits action potential firing in both direct-and indirect-pathway striatal projection
neurons (SPNs) through vesicular release of the inhibitory transmitter γ-aminobutyric acid
(GABA). GABA is released directly from dopaminergic axons but in a manner that is independent
of the vesicular GABA transporter VGAT. Instead GABA release requires activity of the vesicular
monoamine transporter VMAT2, which is the vesicular transporter for DA. Furthermore, VMAT2
expression in GABAergic neurons lacking VGAT is sufficient to sustain GABA release. Thus,
these findings expand the repertoire of synaptic mechanisms employed by DA neurons to
influence basal ganglia circuits, reveal a novel substrate whose transport is dependent on VMAT2,
and demonstrate that GABA can function as a bona fide co-transmitter in monoaminergic neurons.
The striatum integrates inputs from cortex, hippocampus, thalamus, amygdala and VTA/SNc
to instruct the selection of appropriate motor actions. Inputs from midbrain DA neurons play
an important role in this process, as evidenced by the psychomotor deficits that arise
following loss of these cells in Parkinson’s disease, or by the occurrence of compulsive and
addictive behaviors upon potentiation of dopaminergic signaling5–7. Through release of DA,
these neurons promote activation of direct pathway SPNs (dSPNs), which express Gαs/olf-
coupled D1 receptors, and inhibit indirect pathway SPNs (iSPNs), which express Gαi/o-
coupled D2 receptors3,5. However, midbrain DA neurons also express neuropeptides8 and a
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research,
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
*Correspondence: bsabatini@hms.harvard.edu.
1Present address: Department of Neurology and Neurological Sciences, Stanford Institute of Neuro-innovation and Translational
Neurosciences (SINTN), Stanford University School of Medicine, 1050 Arastradero Rd, Palo Alto, CA94304
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
AUTHORS CONTRIBUTIONS
N.X.T., J.B.D. and B.L.S. designed the experiments. N.X.T. performed the experiments described in the figures and text and analyzed
the data. J.B.D. performed experiments that initiated this study, devised the injection coordinates, established amperometric recordings
and participated in their acquisition. N.X.T. and B.L.S. wrote the manuscript with contributions from J.B.D.
AUTHOR INFORMATION
Reprints and permissions information is available atwww.nature.com/reprints. The authors declare no competing financial interests.
Readers are welcome to comment on the online version of this article atwww.nature.com/nature. Correspondence and requests for
materials should be addressed to B.L.S. (bsabatini@hms.harvard.edu).
NIH Public Access
Author Manuscript
Nature. Author manuscript; available in PMC 2014 March 06.
Published in final edited form as:
Nature. 2012 October 11; 490(7419): 262–266. doi:10.1038/nature11466.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
subset releases glutamate9–12, suggesting that the net effects of activity in these cells may
not be limited to the actions of DA.
To investigate how DA neurons influence neuronal activity in striatum, we expressed the
light-activated cation channel channelrhodopsin-2 (ChR2)13 inSNc neurons using Cre
recombinase-dependent adeno-associated viruses(AAVs). In Slc6a3IRES-Cre/wt mice, Cre
expression displays high penetrance and specificity for midbrain DA neurons14
(Supplementary Fig. 1). We validated SNc targeting using an AAV encoding Cre-dependent
enhanced green fluorescent protein (EGFP): Fluorescence was restricted to Cre-containing
neurons within SNc, and the vast majority of EGFP-expressing cells (97.9%, n=1587 cells; 3
mice) were immunopositive for the catecholamine biosynthetic enzyme tyrosine
hydroxylase (TH), demonstrating specific expression in DA neurons (Fig. 1a,b;
Supplementary Figs. 1 and 2). Moreover, EGFP+ axons densely innervated dorsal striatum
(Fig. 1c), consistent with their nigrostriatal identity.
Carbon-fiber amperometry confirmed the ability to evoke DA release from ChR2-expressing
axons in slices of dorsal striatum. Brief flashes of blue light (1 ms) reliably evoked DA
transients, which were sensitive to the TH antagonist α-methyl-tyrosine (αMT) and the
VMAT2 antagonists reserpine and tetrabenazine (TBZ) (Fig. 1d,e). Moreover, DA release
required Ca2+ channels, as it was blocked by cadmium, and activation of D2 receptors with
quinpirole reduced DA release, consistent with the effect of DA autoreceptors in
nigrostriatal axons15.
To determine the net effect of DA neuron stimulation on striatal output, we performed
whole-cell current-clamp recordings from dSPNs and iSPNs in brain slices obtained from
Slc6a3IRES-Cre/wt;Drd2-EGFP mice. Whereas action potentials evoked by current steps
occurred at regular intervals under baseline conditions, light presentation reliably
pausedfiring and rapidly hyperpolarized SPNs of both populations (dSPNs: 6.8±1.9 mV,
n=10; iSPNs: 7.0±1.4 mV, n=7) (Fig. 1f,g). The light-evoked pause and hyperpolarization
were unaffected by a cocktail of antagonists targeting DA receptors (dSPNs:6.6±2.2 mV,
n=4; iSPNs:9.5±2.5 mV, n=4; both P>0.05 vs. light only, Mann-Whitney). Instead, they
were abolished by the GABAA receptor antagonist SR95531 (n=4 dSPNs, 7 iSPNs) (Fig.
1f,g), which does not alter DA release (Fig. 1e), implicating the inhibitory transmitter
GABA. These data indicate that DA neurons exert a rapid and strong inhibitory influence on
SPNs through activation of GABAA receptors.
Previous attempts at characterizing DA receptor-independent effects of DA neurons on
SPNs revealed a small, but rapid excitatory influence mediated by corelease of
glutamate9–12. However, these experiments were performed in the presence of GABA
receptor antagonists, precluding the detection of inhibitory influences. To reveal
conductances recruited following DA neuron stimulation, we performed whole-cell voltage-
clamp recordings from dSPNs and iSPNs in dorsal striatum without pharmacological
blockers. When SPNs were held at −70 mV(ECl, the reversal potential for chloride),
nigrostriatal fiber stimulation evoked fast inward currents in ~75% of dSPNs (n=6/8) and
iSPNs (n=16/21) (Fig. 2a–e). These currents displayed similar properties in both cell types
(Fig. 2a–c) and were consequently pooled for analysis: they exhibited peak
amplitudesof40±5 pA (n=22), rise times of 2.6±0.4 ms and decay time constants of 6.8±1.5
ms. Moreover, they reversed at ~0 mV and were sensitive to the AMPA and NMDA
receptor blockers NBQX and CPP(Fig. 2a,b,f), indicating that they are glutamatergic
excitatory postsynaptic currents (EPSCs). Although glutamate release by midbrain DA
neurons was proposed to be limited to mesolimbic fibers innervating ventral striatum12, the
currents reported here in dorsal striatum display similar properties11,12, and are sensitive to
the same pharmacological agents as DA release (Figs. 1e,2f), suggesting a dopaminergic
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origin. Moreover, EPSCs were unaffected by DA receptor antagonists (Fig. 2f), indicating
that glutamate release is not secondary to DA receptor activation.
To isolate conductances that mediate SPN inhibition, the membrane potential was held at the
reversal potential of ionotropic glutamate receptors (~0 mV). Under these conditions, DA
neuron stimulation evoked large outward currents in all recorded dSPNs (n=8) and iSPNs
(n=21) (Fig. 2a–c and Supplementary Fig. 3). Collectively, these currents had peak
amplitudes of 617±78 pA (n=29; range=0.11–1.93 nA), rise times of 2.0±0.2 ms and decay
time constants of 56±4 ms. They reversed at ECl and were blocked by SR95531 and
bicuculine, but not by the GABAC receptor antagonist TPMPA (Fig. 2a,b,g), indicating that
they represent GABAA receptor-mediated inhibitory postsynaptic currents (IPSCs). Similar
observations were made in mice expressing Cre under control of a TH promoter
(Supplementary Fig. 4). Consistent with previous reports11,12, no current remained with both
glutamate and GABAA receptors blocked. Thus, these data show that 1) activation of
dopaminergic terminals rapidly activates ionotropic glutamate and GABA receptors in
SPNs, 2) the resulting currents do not differentially affect dSPNs and iSPNs, and 3)
GABAergic conductances mediate the net inhibitory effect of DA neurons on striatal output.
DA neurons may activate GABAA receptors on SPNs either by recruiting a population of
GABAergic interneurons – a mechanism akin to feed-forward inhibition – or by directly
releasing GABA. Several lines of evidence suggest the latter. First, the latency between light
and IPSC onset averaged 2.2±0.1 ms (n=29; Fig. 2d,e), which maybe too short to
accommodate two synaptic transmission steps at 32–34°C16. Second, GABAergic
conductances preceded or occurred synchronously with EPSCs (Fig. 2d,e), which arise
following glutamate corelease from DA terminals10–12 (Fig. 2h,i). Third, a population of
dopaminergic SNc neurons expresses mRNA for glutamic acid decarboxylase (GAD-65)17,
indicating that they may synthesize GABA. We reasoned that if GABA originates from
dopaminergic terminals, optically-evoked IPSCs, EPSCs and extracellular DA should be
similarly affected by pharmacological agents and persist under conditions that prevent
disynaptic transmission. Indeed, IPSCs in SPNs were reduced by quinpirole, eliminated by
cadmium, but insensitive to glutamate and DA receptor inhibitors (Fig. 2g), indicating that
they require Ca2+-dependent release of a transmitter other than glutamate or DA. Moreover,
light-evoked IPSCs, EPSCs and DA release were abolished in the presence of the voltage-
gated Na+ channel blocker tetrodotoxin (TTX), revealing that ChR2-mediated depolarization
is not sufficient to trigger transmitter release from nigrostriatal axons (Fig. 2h,i).
Neurotransmission can be rescued from directly-illuminated ChR2-expressing terminals in
the presence of TTX by providing additional depolarization with the voltage-gated K+
channel blocker 4-aminopyridine (4AP)18. Accordingly, IPSCs, EPSCs and DA release
recovered upon co-application of TTX and 4AP (Fig. 2h,i), indicating that GABA,
glutamate and DA are directly released from dopaminergic terminals.
The vesicular GABA transporter VGAT (encoded by Slc32a1)is the only transporter known
to package GABA into synaptic vesicles and is considered indispensable for inhibitory
synaptic transmission19. We generated conditional knockout (cKO) mice in which VGAT is
specifically deleted from DA neurons (Slc6a3IRES-Cre/wt;Slc32a1lox/lox mice), predicting that
ChR2-evoked IPSCs would be abolished. However, light-evoked IPSCs and EPSCs were
unaffected in these mice (Fig. 3a,b,g,j), indicating that VGAT is not responsible for
vesicular loading of GABA in DA neurons. We instead hypothesized that GAD-65 may
synthesize GABA from its metabolic precursor glutamate once inside synaptic vesicles. If
correct, preventing glutamate loading into synaptic vesicles by genetically ablating the
vesicular glutamate transporter 2 (VGLUT2; encoded by Slc17a6) from DA neurons
(Slc6a3IRES-Cre/wt;Slc17a6lox/lox mice) should eliminate IPSCs and EPSCs10. However,
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conditional deletion of VGLUT2 abolished light-evoked EPSCs in SPNs without affecting
IPSC amplitude or latency (Fig. 3c,g,j), excluding this possibility.
These results indicate that GABA release originates in nigrostriatal terminals but is
independent of VGAT and VGLUT2, suggesting the existence of an alternate vesicular
transporter with previously unidentified activity for GABA. Consistent with this, IPSCs
were eliminated in slices obtained from mice treated with the VMAT2 antagonists reserpine,
Ro4-1284 or TBZ and largely recovered upon Ro4-1284 and TBZ washout (Fig. 3d–g). The
same manipulation did not affect EPSCs or VGAT-dependent GABA release from SPNs
(Supplementary Fig. 5), and we confirmed that DA itself does not function as a GABAA
receptor agonist in SPNs (Supplementary Fig. 6). Moreover, DA depletion with αMT(Fig.
1e) had no effect on IPSCs or EPSCs (Fig. 3g). We therefore conclude that VMAT2, but not
DA, is required for the release of GABA by DA neurons.
If GABAergic IPSCs depend on VMAT2solely for GABA transport into synaptic vesicles,
IPSCs should be restored in reserpine-treated mice by expressing VGAT in DA neurons
(Fig. 3h). Accordingly, in Slc6a3IRES-Cre/wt mice injected with AAV encoding Cre-
dependent VGAT (AAV-DIO-VGAT) and treated with reserpine, optogenetic stimulation of
nigrostriatal axons elicited large SR95531-sensitive IPSCs exhibiting synaptic latencies
(Fig. 3g–j) and rise times (1.8±0.3, n=10; P>0.05 vs. control, Mann-Whitney)
indistinguishable from IPSCs observed in untreated mice. Together, these data indicate that
presynaptic DA terminals contain GABA, the synaptic packaging of which requiresVMAT2
but not VGAT.
VMAT2 transportsa variety of substrates20, including catecholamines, serotonin and
histamine. Although GABA does not bear structural resemblance to known VMAT2
substrates, our findings suggest that VMAT2 may function as a vesicular GABA transporter.
To test this possibility, we asked if VMAT2 can substitute for VGAT to sustain GABA
release in a population of non-monoaminergic GABAergic neurons. Specifically, we
attempted to restore GABA release in iSPNs devoid of VGAT by exogenously expressing
VMAT2. We conditionally excised the gene encoding VGAT in iSPNs and virally expressed
ChR2 in these cells to allow monitoring of GABA release from iSPN axon collaterals onto
neighboring dSPNs as light-evoked IPSCs21 (Fig 4a). Whereas optogenetic stimulation of
iSPNs in control mice (Adora2a-Cre;Slc32a1lox/wt;Drd2-EGFP) reliably evoked large IPSCs
in dSPNs, IPSCs were almost entirely abolished in dSPNs from VGAT cKO mice
(Adora2a-Cre;Slc32a1lox/lox;Drd2-EGFP) (Fig. 4b,c,e), confirming the dependence of
vesicular GABA transport in SPNs on VGAT19,21. By contrast, in VGAT cKO mice
transduced with Cre-dependent VMAT2 (AAV-DIO-VMAT2), light reliably evoked large,
short-latency IPSCs (Fig. 4d–f). Thus, VMAT2 expression in GABAergic neurons can
functionally replace VGAT and sustain inhibitory synaptic transmission.
Midbrain DA neurons are critical for the initiation, selection and reinforcement of motor
actions and have been implicated in motor, cognitive and addictive disorders1–7. Their
effects are largely attributed to the slow neuromodulatory actions of DA receptors1–3. Our
studies show that DA neurons additionally exert a rapid and potent inhibitory influence on
the activity of SPNs by releasing another transmitter that activates GABAA receptors.
Release of this transmitter depends on VMAT2activity, indicating that VMAT2 or a
molecular complex requiring VMAT2 activity packages it in synaptic vesicles together with
DA. The simplest model accounting for our data is that GABA is the transmitter packaged
by VMAT2 and released onto SPNs. However, we cannot rule out that another molecule
present in iSPNs and DA neurons, acting as a GABAA receptor agonist, and serving as a
substrate for both VMAT2 and VGAT fulfills that role.
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It is estimated that 5–10% of SNc DA neurons express GAD-65 and <1% express
VGLUT2in rodents10,17,22. Therefore, distinct subpopulations of DA neurons may release
GABA and glutamate, and reliable detection of IPSCs and EPSCs may result from
innervation of SPNs by multiple DA neurons23. Alternatively, GABAergic transmission
may be common to midbrain DA neurons as any means of acquiring GABA, such as plasma
membrane uptake, would result in vesicular transport. GAD expression varies in response to
neuronal activity24 and damage25, suggesting that GABAergic signaling from DA neurons
may be altered by drug abuse or Parkinson’s disease.
Since all monoaminergic neurons express VMAT2, our results imply that GABA corelease
may extend to adrenergic, noradrenergic, serotonergic, histaminergic, as well as other
dopaminergic neurons. Indeed, GABA release was reported from dopaminergic amacrine
cells in the retina26 and periglomerular cells in the olfactory bulb27, although dependence on
VMAT2 remains to be determined. Moreover, a considerable fraction (up to 80%) of
monoaminergic neurons in locus coeruleus28, hypothalamus29, and raphe nuclei30 contain
GABA or express GAD. Together, these findings expand the repertoire of synaptic
mechanisms available to monoaminergic cells and suggest that perturbations of GABA co-
transmission might contribute to the etiology of monoaminergic pathologies or to the
therapeutic efficacy of VMAT2 antagonists.
ONLINE METHODS
Mice
Knock-in mice bearing an internal ribosome entry site (IRES)-linked Cre recombinase gene
downstream of the gene Slc6a3, which encodes the plasma membrane DA transporter DAT
(referred to as Slc6a3IRES-Cre mice)31 were obtained from Jackson Labs (stock # 006660).
Homozygous (Slc6a3IRES-Cre/IRES-Cre) and heterozygous (Slc6a3IRES-Cre/wt) animals were
bred with Drd2-EGFPtransgenic mice (GENSAT, founder line S118), which express EGFP
under control of a bacterial artificial chromosome (BAC) containing the D2 receptor
genomic locus to permit distinction between direct and indirect pathway SPNs32.
Alternatively, Slc6a3IRES-Cre mice were crossed with mice bearing a Cre-dependent
TdTomato reporter transgene (Ai14; Jackson Labs, stock #007914; referred to as
Rosa26lsl-tdtomato mice) to reveal the distribution of Cre+ cells33. Mice in which the second
exon of Slc32a1, which encodes the vesicular GABA transporter (VGAT), or Slc17a6,
which encodes the vesicular glutamate transporter 2 (VGLUT2) are flanked by lox sites
(Slc32a1lox and Slc17a6lox, respectively) were kindly provided by Brad Lowell (Beth Israel
Deaconess Medical Center)34,35. Conditional deletion of VGAT or VGLUT2 from Cre-
expressing DA neurons was achieved by crossing Slc6a3IRES-Cre/wt;Slc32a1lox/wt and
Slc32a1lox/lox;Drd2-EGFP mice, or Slc6a3IRES-Cre/wt;Slc17a6lox/wt and Slc17a6lox/lox mice,
respectively. No differences were observed between control Slc6a3IRES-Cre mice and
Slc6a3IRES-Cre mice carrying a single floxed allele of Slc32a1 or Slc17a6, so data from these
animals were pooled. iSPNs were genetically targeted using Adora2a-Cre BAC transgenic
mice (GENSAT, founder line KG139), which express Cre under transcriptional control of
the adenosine A2A receptor genomic promoter36. Conditional deletion of VGAT in Cre-
expressing iSPNs was achieved by crossing Adora2a-Cre;Slc32a1lox/wt and
Slc32a1lox/lox;Drd2-EGFP mice. Other lines employed include Th-Cre transgenic mice
(Jackson Labs, stock # 008601), Gad1IRES-EGFP knock-in mice37 and Drd1a-Cre BAC
transgenic mice (GENSAT, fonder line EY262). With the exception of Slc6a3IRES-Cre and
Rosa26lsl-tdtomato mice, which were maintained on a C57BL/6 background, all other strains
were maintained on a mixed background of C57BL/6 and FVB. All experimental
manipulations were performed in accordance with protocols approved by the Harvard
Standing Committee on Animal Care following guidelines described in the US National
Institutes of Health Guide for the Care and Use of Laboratory Animals.
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Virus preparation
Conditional expression of the light-gated non-selective cation channel channelrhodopsin-2
(ChR2, H134R variant) in Cre-containing neurons was achieved using a recombinant adeno-
associated virus (AAV) encoding a double-floxed inverted open reading frame (DIO) of the
ChR2-mCherry fusion protein under transcriptional control of the EF1α promoter (AAV-
DIO-ChR2; http://www.stanford.edu/group/dlab/optogenetics/sequence_info.html#dio).
Cre-dependent AAV vectors encoding EGFP (AAV-DIO-EGFP), VGAT
(NM_009508.2;AAV-DIO-VGAT; Addgene plasmid39320) or VMAT2 (NM_172523.3;
AAV-DIO-VMAT2; Addgeneplasmid39339) were generated by replacing the ChR2-
mCherry coding sequence using Asc1 and Nhe1 restriction sites (Genscript). These viral
vectors were subsequently packaged (serotype 8) by a commercial vector core facility
(University of North Carolina). All AAVs were stored in undiluted aliquots at a working
concentration >1012 genomic copies per ml at −80°C until intracranial injection.
Stereotaxic intracranial injections
Male and female mice (postnatal day 18–25) were anesthetized with isoflurane and placed in
a small animal stereotaxic frame (David Kopf Instruments). After exposing the skull under
aseptic conditions, a small burr hole was drilled and AAVs were injected (0.5–1 μl total
volume) unilaterally through a pulled glass pipette at a rate of 100 nl·min−1 using a UMP3
microsyringe pump (World Precision Instruments). Injection coordinates were 0.8 mm
anterior from Lambda, 1.3 mm lateral and 4.4 mm below pia for SNc, and 0.5 mm anterior
from Bregma, 1.75 mm lateral, and 2.7 mm below pia for dorsal striatum. After surgical
procedures, mice were returned to their home cage for >21 days to allow for maximal gene
expression. To identify striatum-projecting neurons in ventral midbrain,
Slc6a3IRES-Cre/wt;Rosa26lsl-tdtomato/wt mice were injected with 0.1–0.2 μl fluorescent latex
microspheres (Green Retrobeads, Lumafluor) in dorsal striatum (same coordinates as above)
and allowed to recover in their home cage for 7 days before processing their brain for TH
immunolabeling.
Immunocytochemistry
Mice were deeply anesthetized with isoflurane and perfused transcardially with 4%
paraformaldehyde in 0.1 M sodium phosphate buffer. Brains were post-fixed for 1–3 days,
washed in phosphate buffered saline (PBS) and sectioned (40–50 μm) coronally
(Vibratome). Free-floating sections were permeabilized/blocked with 5% normal goat serum
in PBS with 0.3% Triton X-100 (PBST) for 2 h at room temperature and incubated with
primary antibodies at 4°C overnight and with secondary antibodies for 2 h at room
temperature in PBST supplemented with 1% normal goat serum. Brain sections were
mounted on superfrost slides, dried and coverslipped with ProLong antifade reagent with
DAPI (Molecular Probes). Primary antibodies used include: rabbit anti-TH (1:2000; AB152,
Millipore), mouse anti-TH (1:1000; 22941, ImmunoStar) and rabbit anti-VMAT2 (1:2000;
ab81855, Abcam). Alexa Fluor 488-and 647-conjugated secondary antibodies to rabbit and
mouse (Invitrogen) were diluted 1:1000. Endogenous TdTomato and EGFP fluorescence
were not immuno-enhanced. Whole sections were imaged with an Olympus VS110 slide
scanning microscope. High resolution images of regions of interest were subsequently
acquired with a Zeiss LSM 510 META confocal microscope (Harvard NeuroDiscovery
Center). Images represent maximum intensity projections of 3–7 μm confocal stacks.
Slice preparation
Acute brain slices were obtained from 40–218 d old mice (median = 74 d) using standard
techniques. Mice were anesthetized by isoflurane inhalation and perfused cardiacly with ice-
cold artificial cerebrospinal fluid (ACSF) containing (in mM) 125 NaCl, 2.5 KCl, 25
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NaHCO3, 2 CaCl2, 1 MgCl2, 1.25 NaH2PO4 and 11 glucose (295 mOsm·kg−1). Cerebral
hemispheres were removed, placed in cold choline-based cutting solution (consisting of (in
mM): 110 choline chloride, 25 NaHCO3, 2.5 KCl, 7 MgCl2, 0.5 CaCl2, 1.25 NaH2PO4, 25
glucose, 11.6 ascorbic acid, and 3.1 pyruvic acid), blocked and transferred into a slicing
chamber containing ice-cold choline-based cutting solution. Parasagittal slices of striatum
(275 μm thick) were cut with a Leica VT1000s vibratome, transferred for 10–20 min to a
holding chamber containing ACSF at 34°C and subsequently maintained at room
temperature (20–22°C) until use. All recordings were obtained within 4 hours of slicing.
Both cutting solution and ACSF were constantly bubbled with 95% O2/5% CO2.
Electrophysiology
Individual slices were transferred to a recording chamber mounted on an upright microscope
(Olympus BX51WI) and continuously superfused (2–3 ml·min−1) with ACSF warmed to32–
34°C by passing it through a feedback-controlled in-line heater (SH-27B; Warner
Instruments). Cells were visualized through a 40X water-immersion objective with either
infrared differential interference contrast optics or epifluorescence to identify EGFP+ iSPNs
and striatal regions displaying the highest density of ChR2-mCherry+ axonal arbors.
Epifluorescence was used sparingly to minimize ChR2 activation prior to recording. Whole-
cell voltage-and current-clamp recordings were made from dSPNs or iSPNs in anterior
dorsolateral and dorsomedial striatum within 300 μm of the callosal-striatal border. dSPNs
and iSPNs were identified based on the respective absence or presence of EGFP
fluorescence and their firing properties. Patch pipettes (2–4 MΩ) pulled from borosilicate
glass (G150F-3, Warner Instruments) were filled either with a Cs+-based low Cl− internal
solution containing (in mM) 135 CsMeSO3, 10 HEPES, 1 EGTA, 3.3 QX-314 (Cl− salt), 4
Mg-ATP, 0.3 Na-GTP, 8 Na2-Phosphocreatine (pH 7.3 adjusted with CsOH; 295
mOsm·kg−1)for voltage-clamp recordings, or with a K+-based low Cl− internal solution
composed of (in mM) 135 KMeSO3, 3 KCl, 10 HEPES, 1 EGTA, 0.1 CaCl2, 4 Mg-ATP, 0.3
Na-GTP, 8 Na2-Phosphocreatine (pH 7.3 adjusted with KOH; 295 mOsm·kg−1)for current-
clamp recordings. Bath solutions for whole-cell recordings did not contain drugs unless
specified otherwise. For all voltage-clamp experiments, errors due to the voltage drop across
the series resistance (<20 MΩ) were left uncompensated. Membrane potentials were
corrected for a ~8 mV liquid junction potential. To activate ChR2-expressing fibers, light
from a 473 nm laser (Optoengine) was focused on the back aperture of the microscope
objective to produce wide-field illumination of the recorded cell. Brief pulses of light (1 ms
duration; 6.5–10.0 mW·mm−2 under the objective) were delivered at the recording site at 30
s intervals under control of the acquisition software. For current-clamp recordings,
depolarizing current steps evoking 10–20 Hz trains of action potentials were applied at
regular intervals (10–15 s) either alone or in combination with a 1 ms flash of blue light.
Amperometric recordings
Constant-potential amperometry was carried out using homemade glass-encased carbon-
fiber microelectrodes (7 μm diameter, 50–100 μm length) placed ~50 μm within dorsal
striatum slices and held at a constant voltage of +400–600 mV vs. Ag/AgCl via a
Multiclamp 700B amplifier (Molecular Devices). Electrodes were calibrated with fresh 5
μM dopamine standards in ACSF using fast-scanning cyclic voltammetry (from −0.5 V to
0.9 V, and back to −0.5 V at a rate of 280 mV·ms−1 every 100 ms, with the electrode held at
0 V between scans) to determine the optimal oxidation potential, followed by constant-
potential amperometry of dopamine flow-in to permit conversion of current amplitude to
extracellular dopamine concentration. Dopaminergic terminals surrounding the electrode
were stimulated with 1 ms flashes of blue laser light (6.5–10.0 mW·mm−2)delivered at 2–3
min intervals.
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Reagents
Drugs (all from Tocris, unless specified otherwise) were applied via bath perfusion:
SR95531 (10 μM), (−)biccuculine (20 μM), (1,2,5,6-Tetrahydropyridin-4-
yl)methylphosphinic acid (TPMPA; 20 μM), 2,3-dihydroxy-6-nitro-7-sulfamoyl-
benzo(f)quinoxaline (NBQX; 10 μM), R,S-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic
acid (CPP; 10 μM), tetrodotoxin (TTX; 1 μM), 4-aminopyridine (4AP; 0.1–1 mM), CdCl2
(Sigma, 30 μM) and(−)quinpirole (10 μM). The cocktail of antagonists used to broadly
target D1 and D2 receptor families (D1/2R antagonists)consisted of SCH23390 (1 μM),
SKF83566 (1 μM), (−)sulpiride (10 μM) and L-741,626 (1 μM). To inhibit monoaminergic
vesicular transport and deplete transmitter-filled vesicles, Slc6a3IRES-Cre mice were injected
intraperitoneally with either the irreversible VMAT inhibitor reserpine (5 mg·kg−1) 24 h
prior to slicing, the reversible VMAT antagonist Ro4-1284 (Sigma, 15 mg·kg−1) 1 h prior to
slicing, or the competitive and selective VMAT2 antagonist tetrabenazine (TBZ; 5 mg·kg−1)
2 h prior to slicing. To deplete presynaptic terminals of dopamine, Slc6a3IRES-Cre mice were
administered the tyrosine hydroxylase antagonist α-methyl-DL-tyrosine methyl ester
hydrochloride (αMT; Sigma, 250 mg·kg−1 i.p.) 3 h and 1 h before slicing. Brain sections
from these animals were prepared as described above, but were recovered and incubated in
ACSF containing 1 μM reserpine, 10 μM Ro4-1284, 50 μM TBZ, or 30 μM αMT,
respectively. Half of the slices obtained from Ro4-1284 and TBZ-treated mice were kept >1
h in regular ACSF before recording to allow for drug washout and resumption of
neurotransmitter transport into synaptic vesicles (washout condition in Figs. 1e and 3g).
Data acquisition and analysis
Membrane currents and potentials were amplified and low-pass filtered at 3 kHz using a
Multiclamp 700B amplifier (Molecular Devices), digitized at 10 kHz and acquired using
National Instruments acquisition boards and a custom version of ScanImage written in
MATLAB (Mathworks)38. Amperometry, electrophysiology and imaging data were
analyzed offline using Igor Pro (Wavemetrics) and ImageJ (NIH). In figures, amperometry
and voltage-clamp traces represent the averaged waveform of 3–5 consecutive acquisitions.
Detection threshold for IPSCs and EPSCs was set at 10 pA. Averaged waveforms were used
to obtain current latency, peak amplitude, 10–90% rise time and decay time. Current onset
was measured using a threshold set at 3 standard deviations of baseline noise. Peak
amplitudes were calculated by averaging over a 2 ms window around the peak. For
pharmacological analyses in Figs. 1e, 2f, 2g and 2i, the peak amplitude of 3 consecutive
light-evoked responses 3–4 min following drug perfusion onset were averaged, normalized
to baseline averages and compared statistically to values obtained at corresponding times in
control preparations bathed in ACSF. Data (reported in text and figures as mean ± s.e.m.)
were compared statistically using the following: Mann-Whitney rank sum test, Kruskal-
Wallis analysis of variance (ANOVA) with Dunn’s multiple comparison test, and two-way
ANOVA followed by Bonferroni post-hoc tests, as indicated in the text. P values smaller
than0.05 were considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. DA neuron stimulation inhibits SPNs
a. Coronal midbrain section from a Slc6a3IRES-Cre/wt mouse transduced with a Cre-
dependent EGFPAAV (green). DA neurons immunolabeled for TH (red). DAPI(blue),
nuclear stain. b. Higher magnification of boxed area in a. Although expression levels vary
greatly, the overwhelming majority of EGFP+ cells are TH+. c. EGFP+ SNc neurons densely
innervate dorsal striatum (dStr). vStr; ventral striatum. d. Schematic of carbon-fiber
recording configuration in a sagittal brain slice. ChR2+ DA neurons depicted red, laser
illumination area blue. e. Left, light stimulation (blue) of DA terminals in dorsal striatum
evoked cadmium-, reserpine-, TBZ-and αMT-sensitive DA release measured by
amperometry. Stimulation artifacts blanked for clarity. Right, mean (n=4–19) peak
extracellular DA concentration following optogenetic stimulation of nigrostriatal axons. DA
transients recovered upon TBZ washout (wash). Asterisk, P<0.05vs. ACSF(Mann-Whitney).
f, g. Left, membrane potential responses of a dorsal striatum dSPN(f) or iSPN(g) to current
injection (1.3 s, bottom) and ChR2-mediated stimulation of DA axons(1 ms, blue). Right,
average normalized duration of 3 consecutive interspike intervals (norm. ISI) that precede,
straddle or follow the light flash(positions ‘−1’, ‘0’ and ‘+1’, respectively) upon ChR2
stimulation in ACSF (blue), DA receptor blockers (D1/2R antagonists = SCH23390
+SKF83566 + sulpiride +L-741,626; green) or SR95531(GABAA receptor blocker; purple).
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Black, light prevented from entering the sample. n=14dSPNs, 11iSPNs. Asterisk,
P<0.05(two-way ANOVA). Data in e, f and g represent mean±s.e.m.
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Figure 2. DA neurons directly release GABA onto SPNs
a. Evoked current responses from an iSPN held at indicated potentials (Vh) to optogenetic
activation of nigrostriatal axons(1 ms, blue)upon sequential bath application ofSR95531 and
NBQX/CPP. b. As in a for a dSPN with antagonists applied in reverse order. c. Mean IPSC
(red) and EPSC (gray) absolute amplitudes in dSPNs (n=8) and iSPNs (n=21). Asterisk,
P<0.05 vs. IPSC (Mann-Whitney). d. Normalized IPSCs and EPSCs from a (dark) and b
(light) shown on an expanded time scale. Blue, light presentation. e. Average (n=29 SPNs)
IPSC(red) and EPSC (gray) latencies from light onset to current onset (circle), half maximal
amplitude (triangle) and peak amplitude (square). IPSCs are not delayed compared to
EPSCs. f, g. Mean(n=3–18) EPSC(f) and IPSC(g) amplitudes under control conditions
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(ACSF) or in indicated antagonists normalized to baseline. Asterisk, P<0.05vs. ACSF
(Mann-Whitney). h. Amperometric DA transients (black) and current responses of a
voltage-clamped iSPN (Vh=0 mV, red; Vh=−70 mV, gray) to DA neuron stimulation under
baseline conditions (left), in TTX (middle), and following co-application of TTX and 4AP
(right). i. Extracellular DA concentration (black), IPSC amplitude (red) and EPSC amplitude
(gray) evoked by ChR2 stimulation across conditions normalized to baseline. Data from
ACSF condition same as in Figs. 1e and 2f, g. Asterisk, P<0.05vs. ACSF; ampersand,
P<0.05 vs. TTX (Mann-Whitney). Error bars denote s.e.m.
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Figure 3. GABA release from DA neurons requires VMAT2butnot VGAT
a–c. Representative ChR2-evoked (1 ms, blue) IPSCs (red, Vh=0 mV) and EPSCs (gray, Vh=
−70 mV) from SPNs in Slc6a3IRES-Cre/wt (control, a), Slc6a3IRES-Cre/wt;Slc32a1lox/lox
(VGAT cKO, b), and Slc6a3IRES-Cre/wt;Slc17a6lox/lox (VGLUT2 cKO, c) mice. d–e. As in a
for control Slc6a3IRES-Cre/wt mice treated in vivo and in vitro with the VMAT2 antagonists
reserpine (d), Ro4-1284 (e) or TBZ (f). g. Mean IPSC (red) and EPSC (gray) amplitudes
across conditions (n=4–33). Washout, slices obtained from mice treated in vivo with TBZ or
Ro4-1284 and subsequently allowed to recover in vitro for >1 h in ACSF. Asterisk,
P<0.05vs. ACSF; ampersand, P<0.05vs. TBZ/Ro4-1284; double dagger, P<0.05 vs.
reserpine (Kruskal-Wallis). h. Schematic of working hypothesis: Provided DA neurons
contain cytosolic GABA, viral expression of reserpine-resistant VGAT in DA neurons
should rescue GABA transport into synaptic vesicles (SVs) and IPSCs in reserpine-treated
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mice. Note that VGAT might also incorporate into VMAT2− vesicles. i. Voltage-clamp
recording (Vh=0 mV, red; Vh=−70 mV, gray) from a reserpine-treated iSPN upon
optogenetic stimulation (1 ms, blue) of VGAT-expressing DA axons. j. IPSC onset latencies
(gray, individual cells; red, average)did not differ across conditions. res, reserpine.
GABAergic nature of outward currents (Vh=0 mV) in b, c and i was confirmed with
SR95531 (pink). Error bars denote s.e.m.
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Figure 4. VMAT2 functions as a vesicular GABA transporter
a. Experimental setup: ChR2 was selectively expressed in Cre-containing iSPNs of mice
with one (control; Adora2A-Cre;Slc32a1lox/wt;Drd2-EGFP mice) or both alleles of the gene
encoding VGAT flanked by lox sites (VGAT cKO; Adora2A-Cre;Slc32a1lox/lox;Drd2-EGFP
mice). VGAT cKO + VMAT2, an AAV encoding Cre-dependent VMAT2 (AAV-DIO-
VMAT2) was co-injected with AAV-DIO-ChR2 in the striatum of VGAT cKO mice to
rescue GABA release from iSPNs. b–d. Voltage-clamp recordings (Vh=0 mV) of axon-
collateral IPSCs in dSPNs evoked by optogenetic stimulation (1 ms, blue) of iSPNs in the
absence (red) or presence (pink) ofSR95531 in control (b), VGAT cKO (c) and VGAT cKO
+ VMAT2 (d) mice. Insets: iSPN presynaptic terminal schematic illustrating experimental
conditions. Red triangles, GABA. e. Summary histogram (mean±s.e.m.) of experiments in
b–d (n=10–15 dSPNs). Asterisk, P<0.05vs. control and VGAT cKO+VMAT2 (Kruskal-
Wallis); ampersand, P<0.05 vs. IPSC without SR95531 (Mann-Whitney). f. IPSC onset
latencies from light presentation onset (gray, individual cells; red, mean±s.e.m.) in control
(Adora2A-Cre;Slc32a1lox/wt;Drd2-EGFP mice) and VGAT cKO+VMAT2 mice (Adora2A-
Cre;Slc32a1lox/lox;Drd2-EGFP mice transduced with AAV-DIO-VMAT2 in striatum).
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